Pure Global
NCT05784610

Interest of the Automated Management of Deep Neuromuscular Blockade Monitoring (CURATP)

Interest of the Automated Management of Deep Neuromuscular Blockade Monitoring : A Pilot Pre-post Quasi Experimental Study (CURATP)
Poitiers University Hospital·ClinicalTrials.gov·device·Device trialEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Neuromuscular Blockade
Drug/Device/Intervention
Monitorage by TOF/PTC
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Poitiers University Hospital
Location
Poitiers, France
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2022
End date
May 01, 2023
Enrollment
60 participants
Primary outcome

Evaluate the monitoring of deep NMB by automated management of the measurement of depth NMB (ATP mode) compared to non-automated monitoring (PTC/TOF) in order to improve the maintenance of deep NMB during abdominal surgery

Summary

Neuromuscular blockade (NMB) recommendations updated in 2018 by the Société Française
 d'Anesthésie et Réanimation (SFAR) recommend the use of NMB agents to facilitate surgical
 procedure during abdominal surgery by laparotomy or laparoscopy.
 
 This study aims to evaluate deep NMB monitoring with automated management of NMB depth
 measurement (ATP mode) versus non-automated monitoring (PTC/TOF), in order to improve the
 maintenance of deep NMB during abdominal surgery.

ICD-10 classifications
Skeletal muscle relaxants [neuromuscular blocking agents]Poisoning: Skeletal muscle relaxants [neuromuscular blocking agents]Other neuromuscular dysfunction of bladderNeuromuscular dysfunction of bladder, unspecifiedNeuromuscular scoliosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05784610
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05784610 through Pure Global AI's free database. This phase not specified trial is sponsored by Poitiers University Hospital and is currently Enrolling by invitation. The study focuses on Neuromuscular Blockade. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.